Cheryl H. Arrowsmith

Cheryl H. Arrowsmith

SGC Toronto

Arrowsmith

Biography

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto.  Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018, 2019 and 2022. She was elected an AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

2023

Discovery of Nanomolar DCAF1 Small Molecule Ligands.

Li ASM, Kimani S, Wilson B, Noureldin M, González-Álvarez H, Mamai A, Hoffer L, Guilinger JP, Zhang Y, von Rechenberg M, Disch JS, Mulhern CJ, Slakman BL, Cuozzo JW, Dong A, Poda G, Mohammed M, Saraon P, Mittal M, Modh P, Rathod V, Patel B, Ackloo S, Santhakumar V, Szewczyk MM, Barsyte-Lovejoy D, Arrowsmith CH, Marcellus R, Guié MA, Keefe AD, Brown PJ, Halabelian L, Al-Awar R, Vedadi M

J Med Chem. 2023-3-22 . .doi: 10.1021/acs.jmedchem.2c02132

PMID: 36948210

RAS and PP2A activities converge on epigenetic gene regulation.

Aakula A, Sharma M, Tabaro F, Nätkin R, Kamila J, Honkanen H, Schapira M, Arrowsmith C, Nykter M, Westermarck J

Life Sci Alliance. 2023-3-2 . 6(5): .doi: 10.26508/lsa.202301928

PMID: 36858798

Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.

Göricke F, Vu V, Smith L, Scheib U, Böhm R, Akkilic N, Wohlfahrt G, Weiske J, Bömer U, Brzezinka K, Lindner N, Lienau P, Gradl S, Beck H, Brown PJ, Santhakumar V, Vedadi M, Barsyte-Lovejoy D, Arrowsmith CH, Schmees N, Petersen K

J Med Chem. 2023-2-20 . .doi: 10.1021/acs.jmedchem.2c01933

PMID: 36802665

Antecedent chromatin organization determines cGAS recruitment to ruptured micronuclei.

MacDonald KM, Nicholson-Puthenveedu S, Tageldein MM, Khasnis S, Arrowsmith CH, Harding SM

Nat Commun. 2023-2-2 . 14(1):556 .doi: 10.1038/s41467-023-36195-8

PMID: 36732527

Detection of antibodies against the huntingtin protein in human plasma.

Denis HL, Alpaugh M, Alvarez CP, Fenyi A, Barker RA, Chouinard S, Arrowsmith CH, Melki R, Labib R, Harding RJ, Cicchetti F

Cell Mol Life Sci. 2023-1-18 . 80(2):45 .doi: 10.1007/s00018-023-04687-x

PMID: 36651994

2022

Phosphorylation of the DNA repair scaffold SLX4 drives folding of the SAP domain and activation of the MUS81-EME1 endonuclease.

Payliss BJ, Tse YWE, Reichheld SE, Lemak A, Yun HY, Houliston S, Patel A, Arrowsmith CH, Sharpe S, Wyatt HDM

Cell Rep. 2022-10-25 . 41(4):111537 .doi: 10.1016/j.celrep.2022.111537

PMID: 36288699

PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.

Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C, Ailles L

Nat Rev Urol. 2022-10-17 . .doi: 10.1038/s41585-022-00659-1

PMID: 36253570

Dissecting the stability determinants of a challenging de novo protein fold using massively parallel design and experimentation.

Kim TE, Tsuboyama K, Houliston S, Martell CM, Phoumyvong CM, Lemak A, Haddox HK, Arrowsmith CH, Rocklin GJ

Proc Natl Acad Sci U S A. 2022-10-11 . 119(41):e2122676119 .doi: 10.1073/pnas.2122676119

PMID: 36191185

De novo design of immunoglobulin-like domains.

Chidyausiku TM, Mendes SR, Klima JC, Nadal M, Eckhard U, Roel-Touris J, Houliston S, Guevara T, Haddox HK, Moyer A, Arrowsmith CH, Gomis-Rüth FX, Baker D, Marcos E

Nat Commun. 2022-10-3 . 13(1):5661 .doi: 10.1038/s41467-022-33004-6

PMID: 36192397

Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes.

Barghout SH, Mann MK, Aman A, Yu Y, Alteen MG, Schimmer AD, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D

ACS Chem Biol. 2022-9-9 . .doi: 10.1021/acschembio.2c00451

PMID: 36084291